Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 6/20 | 0.58 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.58 |
| ▸ | CDK1 | P06493 | 6/20 | 0.49 |
| ▸ | CDK2 | P24941 | 6/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.49 |
| ▸ | FLT3 | P36888 | 3/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.49 |
| ▸ | CDK9 | P50750 | 3/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.49 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.49 |
| ▸ | CCND3 | P30281 | 1/20 | 0.49 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.49 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.49 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.49 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.49 |
| ▸ | JAK3 | P52333 | 7/20 | 0.48 |
| ▸ | BTK | Q06187 | 3/20 | 0.48 |
| ▸ | AURKA | O14965 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2470406 | 0.91 | NTRK1 (0.55) | BRD4NTRK1CDK1CDK2CDK5 | |
| SCHEMBL2474327 | 0.90 | JAK3 (0.60) | BRD4NTRK1CDK1CDK2CDK5 | |
| SCHEMBL2474359 | 0.89 | NTRK1 (0.56) | BRD4NTRK1CDK1CDK2CDK5 | |
| SCHEMBL4975164 | 0.89 | NTRK1 (0.59) | BRD4NTRK1CDK1CDK2CDK5 | |
| Ammonia Solution, Strong SCHEMBL14052834 | 0.88 | CDK1 (0.57) | BRD4NTRK1CDK1CDK2CDK5 | |
| SCHEMBL2473777 | 0.87 | NTRK1 (0.61) | BRD4NTRK1CDK1CDK2CDK5 | |
| SCHEMBL2475717 | 0.84 | BRD4 (0.46) | BRD4NTRK1CDK2FLT3CCNA2 | |
| SCHEMBL2475718 | 0.84 | NTRK1 (0.60) | BRD4NTRK1CDK1CDK2CDK5 | |
| SCHEMBL2474071 | 0.83 | NTRK1 (0.53) | BRD4NTRK1CDK1CDK2CDK5 | |
| Ammonia Solution, Strong SCHEMBL14053306 | 0.83 | CDK2 (0.51) | BRD4NTRK1CDK1CDK2CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2370415-B1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS INC (US) | 2016-04-20 | — | — | EP | claimed |
| US-8268851-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | claimed |
| EP-2370415-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | Rigel Pharmaceuticals, Inc. (US) | 2011-10-05 | — | — | EP | claimed |
| WO-2010075558-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-01 | — | — | WO | claimed |
| US-20100158921-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-06-24 | — | — | US | claimed |
| EP-2370415-B1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS INC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-8420659-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-20120301486-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | Riger Pharmaceuticals, Inc. | 2012-11-29 | — | — | US | disclosed |
| US-8268851-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20100158921-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100158921-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | BRD4 538/4885NTRK1 4361/4885CDK1 155/4885 |
| US-20120301486-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | BRD4 538/4885NTRK1 4361/4885CDK1 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.